News

Governor Northam Grants $3.4 Million to Advance Research Commercialization

Governor Ralph Northam today announced that 34 small technology-focused businesses in Virginia will receive a total of $3.4 million in Commonwealth Commercialization Fund (CCF) grants to commercialize research in an array of sectors, including agricultural and environmental technologies, autonomous systems, clean energy, cybersecurity, data analytics, life sciences, and space and satellites. These awards mark the inaugural funding round for CCF, which was developed through the Virginia Innovation Partnership Authority (VIPA).

“Facilitating research breakthroughs and getting new technologies out of the lab and into the hands of consumers is key to driving economic growth and creating jobs in the Commonwealth,” said Governor Northam. “I am confident this first round of CCF awards will produce far-reaching benefits and congratulate these innovators and entrepreneurs on their success in developing transformative solutions to improve lives and address some of the most pressing challenges we face.”

CCF was launched in 2020 to promote innovative and collaborative commercialization efforts, consolidating two legacy programs, the Commonwealth Research Commercialization Fund and the Virginia Research Investment Fund. The Fiscal Year 2021 round offered grants of up to $100,000 to advance early-stage technology projects in strategically important industries through product or service development, market research, intellectual property protection, marketing, pilots, and more. Award recipients will provide 1:1 match funding.

“The new Commonwealth Commercialization Fund signals Virginia’s commitment to increasing commercialization outcomes for small Virginia businesses across many industries,” said Secretary of Commerce and Trade Brian Ball. “Early funding is essential in bringing new products and innovations to market and we look forward to watching the awardees’ innovations thrive in the Commonwealth.”

“We are excited to announce these awards from this first solicitation of CCF,” said Bob Stolle, President of VIPA. “VIPA was created to be a catalyst for expanding innovation and entrepreneurship in Virginia with a clear goal of accelerating scientific, technology-based research and commercialization. These awards are just the beginning of our work with companies, universities, and research institutes to advance research from proof-of-concept to commercialization.”

CCF seeks technologies with a high potential for economic development and job creation and that position the Commonwealth as a national leader in science- and technology-based research, development, and commercialization. For more information about the CCF program, visit cit.org/ccf.

A few companies receiving the CCF projects awards, contingent upon acceptance of award terms and conditions, include:

AgroSpheres, Inc. | Mr. Ameer Shakeel
Commercialization of Reliable, Sustainable Crop Protection Products, $100,000, Agricultural and Environmental Technologies, Charlottesville

BEAM Diagnostics, Inc | Dr. Sarah Snider
Commercialization of Beacon: A Digital Platform for Innovative Prediction Tools in Healthcare, $100,000, Life and Health Sciences, Roanoke

Bonumose, Inc. | Mr. Edwin Rogers
Making Healthy Sugar Affordable for the Mass Market, $100,000, Life and Health Sciences, Charlottesville

Cerillo, Inc. | Mr. Kevin Seitter
Development of a Low-Cost, Miniaturized, Field-Deployable ELISA Reader, $100,000, Life and Health Sciences, Charlottesville

Contraline, Inc | Mr. Kevin Eisenfrats
Development of Market Access Strategy for a Novel Male Contraceptive, $99,998, Life and Health Sciences, Charlottesville

Jeeva Informatics Solutions Inc | Mr. Harsha Rajasimha
Remote Touchless Patient Recruitment and Retention Platform for Clinical Research, $100,000, Life and Health Sciences, Vienna

Meru Biotechnologies | Dr. Daniel Rodenhaver
Development and Commercialization of TruBind Technology for Drug Discovery, $95,850, Life and Health Sciences, Richmond

Recent News

05/18/2026

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced the completion of its acquisition of Soleno Therapeutics, Inc., strengthening the company’s leadership in endocrinology and rare disease. The acquisition adds VYKAT™ XR (diazoxide choline) tablets, the first and only approved medicine for hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome, to

05/15/2026

OsteoStrong Expands in Virginia with New Location in Tysons, Virginia

OsteoStrong, a global leader in skeletal strength conditioning, is expanding in Northern Virginia with a new location in Tysons, Virginia, offering residents a cutting-edge, drug-free solution to improve bone density, strength and overall skeletal health in just 10-minute sessions per week. Located at 8609 Westwood Center Drive, Suite 625, Vienna, VA 22182, OsteoStrong Tysons VA

05/15/2026

ATCC Wins Prestigious National Institutes of Health Replication Prize for Advancing Reproducibility in Virus Research

ATCC is a winner of the National Institutes of Health (NIH) Common Fund Replication Prize, a prestigious national competition designed to advance scientific research by identifying strategies to make biomedical research more replicable. ATCC is recognized as one of 35 winners, and one of 15 selected winners for the Replication Exemplars Track. ATCC was recognized